3,050,000 Shares in Chimerix, Inc. (NASDAQ:CMRX) Bought by Rosalind Advisors Inc.

Rosalind Advisors Inc. purchased a new stake in Chimerix, Inc. (NASDAQ:CMRX) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 3,050,000 shares of the biopharmaceutical company’s stock, valued at approximately $10,614,000. Chimerix makes up approximately 5.3% of Rosalind Advisors Inc.’s investment portfolio, making the stock its 4th biggest holding.

A number of other hedge funds have also recently modified their holdings of the stock. Assenagon Asset Management S.A. grew its position in shares of Chimerix by 154.8% during the fourth quarter. Assenagon Asset Management S.A. now owns 817,739 shares of the biopharmaceutical company’s stock worth $2,846,000 after acquiring an additional 496,823 shares during the last quarter. Palumbo Wealth Management LLC acquired a new position in Chimerix during the 4th quarter worth approximately $221,000. Valeo Financial Advisors LLC raised its position in Chimerix by 78.8% in the fourth quarter. Valeo Financial Advisors LLC now owns 146,186 shares of the biopharmaceutical company’s stock worth $509,000 after acquiring an additional 64,420 shares in the last quarter. Peapod Lane Capital LLC purchased a new position in shares of Chimerix in the 4th quarter valued at about $2,626,000. Finally, Connor Clark & Lunn Investment Management Ltd. increased its holdings in Chimerix by 66.8% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company’s stock valued at $321,000 after buying an additional 138,098 shares in the last quarter. 45.42% of the stock is owned by hedge funds and other institutional investors.

Chimerix Price Performance

NASDAQ:CMRX opened at $8.50 on Friday. The business’s 50-day moving average is $5.34 and its two-hundred day moving average is $2.83. Chimerix, Inc. has a 12 month low of $0.75 and a 12 month high of $8.52. The firm has a market capitalization of $764.46 million, a PE ratio of -9.04 and a beta of 0.32.

Chimerix (NASDAQ:CMRX) last issued its quarterly earnings results on Friday, March 21st. The biopharmaceutical company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.01. The business had revenue of $0.06 million during the quarter, compared to analysts’ expectations of $0.31 million. Equities analysts anticipate that Chimerix, Inc. will post -0.99 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. Wedbush reissued a “neutral” rating and issued a $8.55 target price (up previously from $7.00) on shares of Chimerix in a report on Wednesday, March 5th. HC Wainwright restated a “neutral” rating and set a $8.55 target price (down previously from $11.00) on shares of Chimerix in a research report on Wednesday, March 5th. Jefferies Financial Group restated a “hold” rating and issued a $8.50 price target (down previously from $10.00) on shares of Chimerix in a report on Wednesday, March 5th. Finally, StockNews.com initiated coverage on Chimerix in a research report on Saturday, March 15th. They issued a “hold” rating on the stock.

Insider Activity

In other news, CEO Michael T. Andriole sold 7,370 shares of the firm’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $4.52, for a total value of $33,312.40. Following the transaction, the chief executive officer now directly owns 609,603 shares in the company, valued at approximately $2,755,405.56. This trade represents a 1.19 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In the last 90 days, insiders have sold 20,760 shares of company stock worth $91,175. 13.10% of the stock is currently owned by corporate insiders.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.